The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer

Histology and Histopathology

Volumn 29, Issue 1, 2014, Pages 21-31

  Becker, Matheus ^a,b   Müller, Carolina Beatriz ^a,b   De Bastiani, Marco Antônio ^a,b   Klamt, Fábio ^a,b  

^a Instituto de Ciencias Biologicas e da Saude Pontifical Catholic University of Minas Gerais   (Brazil)

^b National Institute of Science and Technology in Translational Medicine (INCT TM)   (Brazil)

Author keywords

Apoptotic index; Clinical outcome; Non small cell lung cancer; Prognosis; Tumor associated macrophages

Indexed keywords

APOPTOSIS; HUMAN; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MACROPHAGE; MORTALITY; PATHOLOGY; PROGNOSIS; REVIEW;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MACROPHAGES; PROGNOSIS;

EID: 84890906410     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Al-Shibli K., Al-Saad S., Donnem T., Persson M., Bremnes R.M. and Busund L.T. (2009). The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 55, 301-312.
2. Allavena P., Sica A., Solinas G., Porta C. and Mantovani A. (2008). The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit. Rev. Oncol./Hematol. 66, 1-9.
3. Anderson C.F. and Mosser D.M. (2002). A novel phenotype for an activated macrophage: the type 2 activated macrophage. J. Leukocyte Biol. 72, 101-106.
4. Arenberg D.A., Keane M.P., DiGiovine B., Kunkel S.L., Strom S.R.B., Burdick M.D., Iannettoni M.D. and Strieter R.M. (2000). Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother. 49, 63-70.
5. Biswas S.K., Sica A. and Lewis C.E. (2008). Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J. Immunol. 180, 2011-2017.
6. Castro M.A.A., Dal'Pizzol F., Zdanov S., Soares M., Müller C.B., Lopes F.M., Zanotto'Filho A., Fernandes M.D.C., Moreira J.C.F. and Shacter E. (2010). CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer. Cancer 116, 3645-3655.
7. Chen J.J., Yao P.-L., Yuan A., Hong T.-M., Shun C.-T., Kuo M.-L., Lee Y.-C. and Yang P.-C. (2003). Up-Regulation of tumor interleukin-8 expression by infiltrating macrophages its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin. Cancer Res. 9, 729-737.
8. Chen J.J.W., Lin Y.C., Yao P.L., Yuan A., Chen H.Y., Shun C.T., Tsai M.F., Chen C.H. and Yang P.C. (2005). Tumor-associated macrophages: the double-edged sword in cancer progression. J. Clin. Oncol. 23, 953-964.
9. da Costa Souza P., Parra E.R., Atanazio M.J., da Silva O.B., Noleto G.S., Ab'Saber A.M., de Morais Fernezlian S., Takagaki T. and Capelozzi V.L. (2012). Different morphology, stage and treatment affect immune cell infiltration and long-term outcome in patients with non-small-cell lung carcinoma. Histopathology 61, 487-596.
10. Dai F., Liu L., Che G., Yu N., Pu Q., Zhang S., Ma J., Ma L. and You Z. (2010). The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC cancer 10, 220.
11. Dworakowska D., Jassem E., Jassem J., Karmolinski A., Dworakowski R., Wirth T., Gruchała M., Rynkiewicz A., Skokowski J. and Yla-Herttuala S. (2005). Clinical significance of apoptotic index in nonsmall cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression. J. Cancer Res. Clin. Oncol. 131, 617-623.
12. Dworakowska D., Jassem E., Jassem J., Karmolinski A., Lapinski M., Tomaszewski D., Rzyman W., Jaskiewicz K., Sworczak K. and Grossman A.B. (2009). Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 66, 127.
13. Elgert K.D., Alleva D.G. and Mullins D.W. (1998). Tumor-induced immune dysfunction: the macrophage connection. J. Leukocyte Biol. 64, 275-290.
14. Estrov Z., Thall P.F., Talpaz M., Estey E.H., Kantarjian H.M., Andreeff M., Harris D., Van Q., Walterscheid M. and Kornblau S.M. (1998). Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 92, 3090-3097.
15. Ghosh M., Crocker J. and Morris A. (2001). Apoptosis in squamous cell carcinoma of the lung: correlation with survival and clinicopathological features. J. Clin. Pathol. 54, 111-115.
16. Gonzalez V.M., Fuertes M.A., Alonso C. and Perez J.M. (2001). Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol. 59, 657-663.
17. Gordon S. (2003). Alternative activation of macrophages. Nature Rev. Immunol. 3, 23-35.
18. Gordon S. and Martinez F.O. (2010). Alternative activation of macrophages: mechanism and functions. Immunity 32, 593-604.
19. Gregory C.D. and Devitt A. (2004). The macrophage and the apoptotic cell: an innate immune interaction viewed simplistically? Immunology 113, 1-14.
20. Gregory C.D. and Pound J.D. (2011). Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J. Pathol. 223, 178-195.
21. Grivennikov S.I., Greten F.R. and Karin M. (2010). Immunity, inflammation, and cancer. Cell 140, 883-899.
22. Heist R.S. and Engelman J.A. (2012). SnapShot: Non-Small Cell Lung Cancer. Cancer Cell 21, 448-448. e442.
23. Hirvikoski P., Kumpulainen E., Virtaniemi J., Pirinen R., Salmi L., Halonen P., Johansson R. and Kosma V.-M. (1999). Enhanced apoptosis correlates with poor survival in patients with laryngeal cancer but not with cell proliferation, bcl-2 or p53 expression. Eur. J. Cancer 35, 231-237.
24. Hodge S., Hodge G., Flower R., Reynolds P.N., Scicchitano R. and Holmes M. (2002). Up-regulation of production of TGF-andbgr; and IL-4 and down-regulation of IL-6 by apoptotic human bronchial epithelial cells. Immunol. Cell Biol. 80, 537-543.
25. Kataki A., Scheid P., Piet M., Marie B., Martinet N., Martinet Y. and Vignaud J.M. (2002). Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J. Lab. Clin. Med. 140, 320.
26. Kawai O., Ishii G., Kubota K., Murata Y., Naito Y., Mizuno T., Aokage K., Saijo N., Nishiwaki Y. and Gemma A. (2008). Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 113, 1387-1395.
27. Kawamura K., Komohara Y., Takaishi K., Katabuchi H. and Takeya M. (2009). Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol. Int. 59, 300-305.
28. Kerr J.F., Wyllie A.H. and Currie A.R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239.
29. Kim D., Min H., Lee K., Kim Y., Oh D., Jeon Y., Lee S., Im S., Chung D. and Kim Y. (2008). High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected nonsmall cell lung cancer. Br. J. Cancer 98, 1118-1124.
30. Komaki R., Fujii T., Perkins P., Ro J.Y., Allen P.K., Mason K.A., Mountain C.F. and Milas L. (1996). Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Int. J. Rad. Oncol. Biol. Phys. 36, 601-605.
31. Komohara Y., Ohnishi K., Kuratsu J. and Takeya M. (2008). Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 216, 15-24.
32. Lankelma J., Dekker H., Luque R.F., Luykx S., Hoekman K., van der Valk P., van Diest P.J. and Pinedo H.M. (1999). Doxorubicin gradients in human breast cancer. Clin. Cancer Res. 5, 1703-1707.
33. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J. and Harris A.L. (1996). Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625-4629.
34. Lewis C.E. and Pollard J.W. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605-612.
35. Lipponen P., Aaltomaa S., Kosma V.-M. and Syrjänen K. (1994). Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur. J. Cancer 30, 2068-2073.
36. Ma J., Liu L., Che G., Yu N., Dai F. and You Z. (2010). The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10, 112.
37. Mantovani A., Sozzani S., Locati M., Allavena P. and Sica A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends immunol. 23, 549-555.
38. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A. and Locati M. (2004). The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677-686.
39. Moertel C.G., Lefkopoulo M., Lipsitz S., Hahn R.G. and Klaassen D. (1992). Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 326, 519-523.
40. Mosser D.M. and Edwards J.P. (2008). Exploring the full spectrum of macrophage activation. Nature Rev. Immunol. 8, 958-969.
41. Muller C., de Barros R., Moreira J. and Klamt F. (2011). Bioinformatics approach for the validation of non-small cell lung cancer biomarkers. Front. Biosci. (Elite edition) 3, 46.
42. Ohri C., Shikotra A., Green R., Waller D. and Bradding P. (2009). Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur. Respir. J. 33, 118-126.
43. Ohtaki Y., Ishii G., Nagai K., Ashimine S., Kuwata T., Hishida T., Nishimura M., Yoshida J., Takeyoshi I. and Ochiai A. (2010). Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J. Thoracic Oncol. 5, 1507-1515.
44. Passaro A., Alesini D., Pochesci A. and Cortesi E. (2012). Erlotinib and Gefitinib for Elderly Patients with Advanced Non-Small-Cell Lung Cancer. Anti-cancer Agents Medicinal Chem. (in press).
45. Pollard J.W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer 4, 71-78.
46. Qian B.Z. and Pollard J.W. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39-51.
47. Reiter I., Krammer B. and Schwamberger G. (1999). Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities. J. Immunol. 163, 1730-1732.
48. Ruffell B., Affara N.I. and Coussens L.M. (2012). Differential macrophage programming in the tumor microenvironment. Trends immunol. 33, 119-126.
49. Savill J. (1997). Apoptosis in resolution of inflammation. J. Leukocyte Biol. 61, 375-380.
50. Schmieder A., Michel J., Schönhaar K., Goerdt S. and Schledzewski K. (2012). Differentiation and gene expression profile of tumorassociated macrophages. In: Seminars in cancer biology. Elsevier.
51. Serhan C.N. and Savill J. (2005). Resolution of inflammation: the beginning programs the end. Nat. immunol. 6, 1191-1197.
52. Shimura S., Yang G., Ebara S., Wheeler T.M., Frolov A. and Thompson T.C. (2000). Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. Cancer Res. 60, 5857-5861.
53. Sica A., Schioppa T., Mantovani A. and Allavena P. (2006). Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717-727.
54. Sica A., Larghi P., Mancino A., Rubino L., Porta C., Totaro M.G., Rimoldi M., Biswas S.K., Allavena P. and Mantovani A. (2008). Macrophage polarization in tumour progression. In: Seminars in cancer biology. Elsevier pp. 349-355.
55. Siddik Z.H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279.
56. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C. and Fedewa S. (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220-241.
57. Singhal S., Vachani A., Antin-Ozerkis D., Kaiser L.R. and Albelda S.M. (2005). Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin. Cancer Res. 11, 3974-3986.
58. Stammler G. and Volm M. (1996). Apoptosis in non-small cell lung cancer as related to drug resistance and prognosis. Apoptosis 1, 95-99.
59. Sulpher J.A., Owen S.P., Hon H., Tobros K., Shepherd F.A., Sabri E., Gomes M., Sekhon H., Liu G. and Canil C.M. (2013). Factors influencing a specific pathologic diagnosis of non-small-cell lung carcinoma. Clin. Lung Cancer 14, 238-244.
60. Tanaka F., Kawano Y., Li M., Takata T., Miyahara R., Yanagihara K., Ohtake Y., Fukuse T. and Wada H. (1999). Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. J. Clin. Oncol. 17, 2728-2728.
61. Tlsty T.D. and Coussens L.M. (2006). Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. Mech. Dis. 1, 119-150.
62. Tong M. and Taira R.K. (2012). Improving the accuracy of therapy descriptions in clinical trials using a bottom-up approach. In: AMIA Annual Symposium Proceedings. Am. Medical Informatics Associat. p. 1393.
63. Toomey D., Smyth G., Condron C., Kelly J., Byrne A.-M., Kay E., Conroy R.M., Broe P. and Bouchier-Hayes D. (2002). Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. Int. J. Cancer 103, 408-412.
64. Törmänen U., Eerola A.K., Rainio P., Vähäkangas K., Soini Y., Sormunen R., Bloigu R., Lehto V.P. and Pääkkö P. (1995). Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res. 55, 5595-5602.
65. Volm M. and Koomägi R. (2000). Relevance of proliferative and proapoptotic factors in non-small-cell lung cancer for patient survival. Br. J. Cancer 82, 1747.
66. Weigert A. and Brüne B. (2008). Nitric oxide, apoptosis and macrophage polarization during tumor progression. Nitric Oxide 19, 95-102.
67. Weigert A., Tzieply N., von Knethen A., Johann A.M., Schmidt H., Geisslinger G. and Brüne B. (2007). Tumor cell apoptosis polarizes macrophages-role of sphingosine-1-phosphate. Mol. Biol. Cell 18, 3810-3819.
68. Welsh T.J., Green R.H., Richardson D., Waller D.A., O'Byrne K.J. and Bradding P. (2005). Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol. 23, 8959-8967.
69. Yamasaki F., Tokunaga O. and Sugimori H. (1997). Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol. Oncol. 66, 439-448.
70. Zhang B., Yao G., Zhang Y., Gao J., Yang B., Rao Z. and Gao J. (2011). M2-Polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics 66, 1879-1886.
71. Zhang Q.-W., Liu L., Gong C.-Y., Shi H.-S., Zeng Y.-H., Wang X.-Z., Zhao Y.-W. and Wei Y.-Q. (2012). Prognostic significance of tumorassociated macrophages in solid tumor: A meta-analysis of the literature. PloS one 7, e50946.